At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MBOT Microbot Medical Inc
Post-Market Trading 11-22 19:03:27 EST
0.9800
+0.0503
+5.41%
盘后0.9762
-0.0038-0.39%
17:02 EST
High0.9890Low0.9114Vol127.69K
Open0.9390D1 Closing0.9297Amplitude8.35%
Mkt Cap16.59MTradable Cap16.35MTotal Shares16.93M
T/O121.36KT/O Rate0.77%Tradable Shares16.68M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Microbot Medical Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  11-14
Microbot Medical Inc reports results for the quarter ended September 30 - Earnings Summary
Microbot Medical Inc expected to post a loss of 17 cents a share - Earnings Preview
Reuters  ·  11-09
Microbot Medical Inc expected to post a loss of 17 cents a share - Earnings Preview
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
Zacks  ·  10-17
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
Microbot Medical Inc - Clinical Trial Results to Be Presented at Medical Conference in Early 2025
THOMSON REUTERS  ·  10-15
Microbot Medical Inc - Clinical Trial Results to Be Presented at Medical Conference in Early 2025
Microbot Medical Announces the Successful Completion of Its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of Liberty® During 2Q 2025
THOMSON REUTERS  ·  10-15
Microbot Medical Announces the Successful Completion of Its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of Liberty® During 2Q 2025
Microbot Medical Inc - to File FDA 510(K) Submission by End of 2024
THOMSON REUTERS  ·  10-15
Microbot Medical Inc - to File FDA 510(K) Submission by End of 2024
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
GlobeNewswire  ·  10-15
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
Microbot Medical Says it Expects to Finish its ACCESS-PVI Robotic Surgical System Clinical Trial Ahead of Schedule
MT Newswires Live  ·  09-30
Microbot Medical Says it Expects to Finish its ACCESS-PVI Robotic Surgical System Clinical Trial Ahead of Schedule
BRIEF-Microbot Medical Accelerates Patient Enrollment Of Human Clinical Trial for LIBERTY
Reuters  ·  09-30
BRIEF-Microbot Medical Accelerates Patient Enrollment Of Human Clinical Trial for LIBERTY
Microbot Medical Accelerates Patient Enrollment of Its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
THOMSON REUTERS  ·  09-30
Microbot Medical Accelerates Patient Enrollment of Its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Microbot Medical Inc - 80% of Patients Completed Follow-up, Trial to Finish Ahead of Schedule
THOMSON REUTERS  ·  09-30
Microbot Medical Inc - 80% of Patients Completed Follow-up, Trial to Finish Ahead of Schedule
Microbot Medical Inc - on Track for FDA 510(K) Submission by End of 2024
THOMSON REUTERS  ·  09-30
Microbot Medical Inc - on Track for FDA 510(K) Submission by End of 2024
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
GlobeNewswire  ·  09-30
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in Its Pivotal Human Clinical Trial for the Liberty Endovascular Robotic Surgical System
THOMSON REUTERS  ·  09-17
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in Its Pivotal Human Clinical Trial for the Liberty Endovascular Robotic Surgical System
Microbot Medical Inc - to File 510(K) Submission With FDA by Year-End
THOMSON REUTERS  ·  09-17
Microbot Medical Inc - to File 510(K) Submission With FDA by Year-End
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
GlobeNewswire  ·  09-17
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Zacks  ·  08-23
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Microbot Medical Advances Telesurgery with Corewell Health Collaboration
TIPRANKS  ·  08-22
Microbot Medical Advances Telesurgery with Corewell Health Collaboration
Microbot Medical Signs Phase 2 Collaboration Agreement With Corewell Health to Advance Remote Telesurgery Using the Liberty® Endovascular Robotic System
THOMSON REUTERS  ·  08-22
Microbot Medical Signs Phase 2 Collaboration Agreement With Corewell Health to Advance Remote Telesurgery Using the Liberty® Endovascular Robotic System
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
GlobeNewswire  ·  08-22
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System

Introduction

Company Name.
Microbot Medical Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, a disposable robotic system for use in endovascular interventional procedures, such as cardiovascular, peripheral, and neurovascular; NovaCross, an intraluminal revascularization device; ViRob, an autonomous crawling micro-robot that cam crawl in various natural spaces within the human body, including blood vessels, the digestive tract and the respiratory system, as well as artificial spaces such as shunts, catheters, ports, etc.; TipCAT, a disposable self-propelled locomotive device for tubular anatomies; and One & Done platform. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Issue price:
--